MEI Pharma logo

MEI PharmaNASDAQ: MEIP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 December 2003

Next earnings report:

08 November 2024

Last dividends:

16 November 2023

Next dividends:

N/A
$20.59 M
-94%vs. 3y high
25%vs. sector
-42%vs. 3y high
3%vs. sector
-94%vs. 3y high
31%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 10 min ago
$3.09+$0.16(+5.46%)

Analysts recommendations

Institutional Ownership

MEIP Latest News

MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research13 February 2024 Sentiment: NEGATIVE

MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to earnings of $1.60 per share a year ago.

All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
Zacks Investment Research29 September 2023 Sentiment: POSITIVE

MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript
Seeking Alpha26 September 2023 Sentiment: POSITIVE

MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2023 Earnings Call Transcript September 26, 2023 5:00 PM ET Company Participants David Walsey - SVP, Corporate Affairs David Urso - President & CEO Jay File - CFO Richard Ghalie - CMO Conference Call Participants Yale Jen - Laidlaw & Company Stephen Willey - Stifel Operator Good day and welcome to the MEI Fiscal Year-End Earnings Call. My name is Gary and I will be the conference facilitator today.

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research11 May 2023 Sentiment: POSITIVE

MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.

What type of business is MEI Pharma?

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

What sector is MEI Pharma in?

MEI Pharma is in the Healthcare sector

What industry is MEI Pharma in?

MEI Pharma is in the Biotechnology industry

What country is MEI Pharma from?

MEI Pharma is headquartered in United States

When did MEI Pharma go public?

MEI Pharma initial public offering (IPO) was on 18 December 2003

What is MEI Pharma website?

https://meipharma.com

Is MEI Pharma in the S&P 500?

No, MEI Pharma is not included in the S&P 500 index

Is MEI Pharma in the NASDAQ 100?

No, MEI Pharma is not included in the NASDAQ 100 index

Is MEI Pharma in the Dow Jones?

No, MEI Pharma is not included in the Dow Jones index

When was MEI Pharma the previous earnings report?

No data

When does MEI Pharma earnings report?

The next expected earnings date for MEI Pharma is 08 November 2024